A large study has found no improvement in overall survival using a combination chemo-immunotherapy regimen for metastatic renal cell carcinoma, compared with immunotherapy alone. While the development of targeted therapies has provided uro-oncologists with a wider variety of treatment options, immunotherapy retains an important role in the management of metastatic renal cell carcinoma.
- Riccardo Autorino
- Giuseppe Di Lorenzo
